Actively Recruiting
Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients
Led by Taiwan Bio Therapeutics Inc. · Updated on 2025-06-06
10
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will test the hypothesis intracoronary administration of OmniMSC-AMI (allogenic bone marrow-derived mesenchymal stem cells) just after finishing the primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients without cardiogenic shock is safe and may provide benefit on improving left ventricular ejection fraction (LVEF) during clinical follow-up.
CONDITIONS
Official Title
Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 20 to 80 years old
- Diagnosed with ST-elevation myocardial infarction (anterior myocardial infarction) confirmed by chest pain onset, 12-lead EKG showing ST-segment elevation in V1-V6 leads of at least 1 mm, and elevated TnT-I levels
- Presenting within 6 hours of acute myocardial infarction onset
- Willing to receive treatment and sign informed consent
You will not qualify if you...
- Age below 20 or above 80 years old
- History of malignancy
- History of sepsis with abnormal white blood cell count
- History of hematologic disorders
- History of AIDS
- Advanced liver cirrhosis
- Chronic kidney disease stage 5 with creatinine clearance less than 15 ml/min
- Acute myocardial infarction occurrence more than 6 hours prior
- Non-first acute myocardial infarction
- Pregnancy or breastfeeding
- Prisoner status
- Cancer treatment within the past 2 years
- Expected lifespan less than 6 months
- Evaluated as unsuitable candidate by principal investigator
- Currently participating in other clinical trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
Actively Recruiting
Research Team
T
Timothy Huang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here